Three additional lots of losartan potassium tablets and two additional lots of losartan potassium/hydrochlorothiazide tablets were under recall, the U.S. Food and Drug Administration said Thursday.

Losartan, a blood pressure medication in the angiotensin II receptor blocker (ARB) class, helps reduce blood pressure by preventing blood vessels from narrowing or constricting.

This covers lot No. JB8912 of Losartan Potassium Hydrochlorothiazide 100 mg or 25 mg tablets in 1,000-count bottles, expiration date 06/2020.

More specifically, the expanded recall includes “an additional 3 lots of Losartan Potassium Tablets USP and 2 lots of Losartan Potassium/Hydrochlorothiazide Tablets, USP,” the FDA said in a ...

The recalled losartan and potassium/hydrochlorothiazide combination tablets contained small amounts of N-nitrosodiethylamine, or NDEA, according to a company notice posted to the Food and Drug ...

Losartan Potassium Hydrochlorothiazide, 100mg/12.5mg, 90-count, lot Nos. BX35C020 and BX35C049 Losartan Potassium Hydrochlorothiazide, 100mg/12.5mg, 1000-count, lot Nos. BX35C022 and BX35C023 ...

The recall involves losartan and potassium/hydrochlorothiazide combination pills found to contain N-Nitroso-N-methyl-4-aminobutyric acid, or NMBA, according to a notice posted by the U.S. Food and ...

The latest recall targets five lots of the drug losartan sold by Torrent Pharmaceuticals Published September 24, 2019 • Updated on September 24, 2019 at 10:09 pm ...

Adverse experiences on losartan/hydrochlorothiazide (43%) were significantly less than with the angiotensin receptor blocker alone (52.6%).

The US FDA has approved the first generic formulations of losartan potassium tablets, ... The 100-mg/12.5-mg losartan/hydrochlorothiazide formulation will also be manufactured by several other ...